Our data reveals that within infused CAR-T cells of defined CD4+:CD8+ composition, CD8+ CAR-T cells in the IP that acquired effector function and proliferated during manufacturing expand and survive in vivo, contributing greatly to the CAR-T cell pool and the anti-tumor response early and late after adoptive transfer. The gene discussed is CD8A; the disease is neoplasm.